Completed Financing and Additional Medical Advisors.

VANCOUVER--(BUSINESS WIRE)--June 28, 1999--

medEra Life Science Corporation (the "Company") is pleased to announce the closing of the private placement announced on April 30, 1999. There were 999,994 units issued on June 24, 1999 at $3.00 per share for gross proceeds of $2,999,982. Each unit will consist of one common share and one non-transferable share purchase warrant (the "warrant"). Each warrant will entitle the holder to purchase one common share of the Company at a price of $3.50 per share for one year. The shares issued pursuant to the private placement are subject to a four-month hold period. Proceeds will be used for continuing development of medbroadcast.com technical, broadcasting and integrated e-commerce infrastructure.

The Company also announces the addition of three new members to the medbroadcast.com Medical Advisory Board:

Matthew H. Liang, MD, MPH

Dr. Liang is Professor of Medicine at Harvard Medical School and Professor of Health Policy and Management at Harvard School of Public Health. He is a graduate of Johns Hopkins University, Harvard Medical School, and the Harvard School of Public Health and is the Director of the Robert B. Brigham Multipurpose Arthritis and Musculoskeletal Diseases Center at the Brigham and Women's Hospital in Boston. Dr. Liang is a consultant to the American Food and Drug Administration, Blue Cross/Blue Shield, the Shriners Hospital System, and the National Institutes of Health, and was named one of the Best Doctors in America.

Christopher R. Shackleton, MD, FRCP,FRCSC

Dr. Shackleton is Director of The Center for Transplantation at Cedars-Sinai Medical Center in Los Angeles. He is a graduate of the University of British Columbia and completed residency and fellowship training at the University of Toronto and Harvard Medical School. From 1988 to 1993, Dr. Shackleton established a provincial organ retrieval team, directed the provincial organ procurement network and co-founded the liver transplant program in Vancouver. In 1993 he introduced microsurgical techniques to the pediatric liver transplant program at the UCLA Liver Transplant Program and from 1995 to 1997 served as Program Director of the Center for Liver Diseases and Transplantation at Cedars-Sinai Medical Center. He has extensive experience in all aspects of abdominal organ transplantation with a record of more than 1100 transplants.

Marc Levine, PhD

Dr. Levine is Professor of Pharmaceutical Sciences at The University of British Columbia. He is a graduate of McGill University and holds an appointment at the Children's and Women's Hospital in Vancouver where he is Chairman of the Pharmacy Research Division and for the past ten years has served on the Clinical Research Ethics Committee of the University. His current research interests include drug-related admissions to hospital, the impact of treatment on quality of life and identification and treatment of depression among the elderly. He is co-editor of "Drug Therapy Decision Making Guide" and has received several teaching awards in Pharmaceutical Sciences.

medEra Life Science Corporation is a public company specializing in the development and management of online medical information and e-commerce services. Working with its strategic technical partner Ericsson Communications Inc., medEra is creating medbroadcast.com, a consumer-oriented medical information website. medEra trades in the United States on the OTCBB under the symbol MEDRF and in Canada as a Senior Board Company on the Vancouver Stock Exchange under the symbol MER.

For additional information, please contact:

re financing:

Arn Schoch, Vice President, Business Development

medEra Life Science Corporation

[phone], ext. 130 or

1-800-663-8068

re corporate information:

Nicola Sutton, Director of Operations

[phone] ext. 127 or

1-800-663-8068

ON BEHALF OF THE BOARD OF DIRECTORS

Michael E. Pezim MD, FACS Chairman and CEO

This News Release may include certain 'forward-looking statements' within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, that may be included in this release, including, without limitation, statements regarding product potential and future plans and objectives of the Company are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. No Stock Exchanges have either approved or disapproved the information contained herein.